Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amneal Pharmaceuticals Inc (AMRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,809,963
  • Shares Outstanding, K 298,570
  • Annual Sales, $ 775,790 K
  • Annual Income, $ -469,290 K
  • 36-Month Beta 1.48
  • Price/Sales 6.28
  • Price/Cash Flow 7.83
  • Price/Book 5.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.28
  • Number of Estimates 7
  • High Estimate 0.33
  • Low Estimate 0.26
  • Prior Year 0.11
  • Growth Rate Est. (year over year) +154.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.06 +7.80%
on 12/14/18
19.32 -15.97%
on 11/29/18
-2.27 (-12.29%)
since 11/16/18
3-Month
15.06 +7.80%
on 12/14/18
24.35 -33.33%
on 09/21/18
-6.57 (-28.83%)
since 09/17/18
52-Week
13.47 +20.53%
on 05/09/18
24.48 -33.68%
on 08/22/18
-2.41 (-12.95%)
since 12/15/17

Most Recent Stories

More News
J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down

A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.

MYL : 28.83 (-0.76%)
JNJ : 127.30 (-4.29%)
TEVA : 17.77 (-3.74%)
AMRX : 16.20 (+0.56%)
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.

JAZZ : 140.06 (-0.36%)
VRTX : 167.91 (-1.26%)
AMRX : 16.20 (+0.56%)
ALKS : 33.01 (+0.58%)
Amneal: 3Q Earnings Snapshot

BRIDGEWATER, N.J. (AP) _ Amneal Pharmaceuticals, Inc. (AMRX) on Wednesday reported third-quarter net income of $7 million, after reporting a loss in the same period a year earlier.

AMRX : 16.20 (+0.56%)
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months

Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is...

IPXL : 18.30 (unch)
AMRX : 16.20 (+0.56%)
These 3 Stocks Are Moving Higher This Month

CORAL GABLES, FL / ACCESSWIRE / October 23, 2018 / Markets were mostly red toward the opening bell on Tuesday. Many equities fell victim to the global issues troubling the . Mainly things like mining stocks...

TTNP : 0.27 (unch)
AMRX : 16.20 (+0.56%)
Amneal and Impax Complete Business Combination

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. ("Impax") today announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"). As...

IPXL : 18.30 (unch)
AMRX : 16.20 (+0.56%)
Apergy Set to Join S&P MidCap 400; 3D Systems to Join S&P SmallCap 600

Apergy Corp. (NYSE: APY) will replace 3D Systems Corp. (NYSE: DDD) in the S&P MidCap 400, and 3D Systems will replace Impax Laboratories Inc. (NASD: IPXL) in the S&P SmallCap 600 effective prior to the...

DDD : 10.55 (-0.75%)
IPXL : 18.30 (unch)
SPGI : 166.23 (-0.23%)
APY : 31.15 (-0.61%)
DOV : 75.12 (-1.57%)
AMRX : 16.20 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AMRX with:

Business Summary

Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories...

See More

Key Turning Points

2nd Resistance Point 17.01
1st Resistance Point 16.56
Last Price 16.26
1st Support Level 15.36
2nd Support Level 14.61

See More

52-Week High 24.48
Fibonacci 61.8% 20.27
Fibonacci 50% 18.98
Fibonacci 38.2% 17.68
Last Price 16.26
52-Week Low 13.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar